Personal information

Verified email addresses

Activities

Employment (1)

Fujian Medical University Cancer Hospital & Fujian Cancer Hospital: Fuzhou, Fujian Province, CN

(Medical Oncology)
Employment
Source: Self-asserted source
Jing Lin

Education and qualifications (1)

Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital: Fuzhou, CN

2022-01-01 to present | deputy director (Department of Medical Oncology)
Qualification
Source: Self-asserted source
Jing Lin

Funding (3)

Joint Funds for the Innovation of Science and Technology, Fujian province (Grant No. 2023Y9412)

Grant
Joint Funds for the Innovation of Science and Technology, Fujian province (FuZhou, CN)
GRANT_NUMBER:

2023Y9412

Source: Self-asserted source
Jing Lin

Natural Science Foundation of Fujian Province (Grant No. 2017J01259)

Grant
Natural Science Foundation of Fujian Province (fuzhou, CN)
GRANT_NUMBER:

2017J01259

Source: Self-asserted source
Jing Lin

Natural Science Foundation of Fujian Province (Grant No. 2023J011254)

Grant
Forestry Department of Fujian Province (FuZhou, CN)
GRANT_NUMBER:

2023J011254

Source: Self-asserted source
Jing Lin

Works (33)

Atezolizumab plus bevacizumab in patients with unresectable or metastatic mucosal melanoma: 3‐year survival update and multi‐omics analysis

Clinical and Translational Medicine
2025-01 | Journal article
Contributors: Jie Dai; Tianxiao Xu; Lifeng Li; Meiyu Fang; Jing Lin; Jun Cao; Xue Bai; Caili Li; Xiaoting Wei; Junjie Gu et al.
Source: check_circle
Crossref

Clinicopathologic features and prognosis of 71 patients with gastric cancer and disseminated intravascular coagulation

PeerJ
2023-11-27 | Journal article
Contributors: Ling Chen; Jing Lin; Yu Chen; Jiami Yu; Xiaojie Wang
Source: check_circle
Crossref

Data from Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study

2023-04-01 | Preprint
Contributors: Lili Mao; Meiyu Fang; Yu Chen; Xiaoting Wei; Jun Cao; Jing Lin; Peng Zhang; Ling Chen; Xiao Cao; Yujun Chen et al.
Source: check_circle
Crossref

Data from Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study

2023-04-01 | Preprint
Contributors: Lili Mao; Meiyu Fang; Yu Chen; Xiaoting Wei; Jun Cao; Jing Lin; Peng Zhang; Ling Chen; Xiao Cao; Yujun Chen et al.
Source: check_circle
Crossref

Supplementary Data from Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study

2023-04-01 | Preprint
Contributors: Lili Mao; Meiyu Fang; Yu Chen; Xiaoting Wei; Jun Cao; Jing Lin; Peng Zhang; Ling Chen; Xiao Cao; Yujun Chen et al.
Source: check_circle
Crossref

Supplementary Data from Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study

2023-04-01 | Preprint
Contributors: Lili Mao; Meiyu Fang; Yu Chen; Xiaoting Wei; Jun Cao; Jing Lin; Peng Zhang; Ling Chen; Xiao Cao; Yujun Chen et al.
Source: check_circle
Crossref

Supplementary Figure from Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study

2023-04-01 | Preprint
Contributors: Lili Mao; Meiyu Fang; Yu Chen; Xiaoting Wei; Jun Cao; Jing Lin; Peng Zhang; Ling Chen; Xiao Cao; Yujun Chen et al.
Source: check_circle
Crossref

Supplementary Figure from Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study

2023-04-01 | Preprint
Contributors: Lili Mao; Meiyu Fang; Yu Chen; Xiaoting Wei; Jun Cao; Jing Lin; Peng Zhang; Ling Chen; Xiao Cao; Yujun Chen et al.
Source: check_circle
Crossref

Supplementary Figure from Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study

2023-04-01 | Preprint
Contributors: Lili Mao; Meiyu Fang; Yu Chen; Xiaoting Wei; Jun Cao; Jing Lin; Peng Zhang; Ling Chen; Xiao Cao; Yujun Chen et al.
Source: check_circle
Crossref

Supplementary Figure from Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study

2023-04-01 | Preprint
Contributors: Lili Mao; Meiyu Fang; Yu Chen; Xiaoting Wei; Jun Cao; Jing Lin; Peng Zhang; Ling Chen; Xiao Cao; Yujun Chen et al.
Source: check_circle
Crossref

Supplementary Table from Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study

2023-04-01 | Preprint
Contributors: Lili Mao; Meiyu Fang; Yu Chen; Xiaoting Wei; Jun Cao; Jing Lin; Peng Zhang; Ling Chen; Xiao Cao; Yujun Chen et al.
Source: check_circle
Crossref

Supplementary Table from Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study

2023-04-01 | Preprint
Contributors: Lili Mao; Meiyu Fang; Yu Chen; Xiaoting Wei; Jun Cao; Jing Lin; Peng Zhang; Ling Chen; Xiao Cao; Yujun Chen et al.
Source: check_circle
Crossref

Supplementary Table from Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study

2023-04-01 | Preprint
Contributors: Lili Mao; Meiyu Fang; Yu Chen; Xiaoting Wei; Jun Cao; Jing Lin; Peng Zhang; Ling Chen; Xiao Cao; Yujun Chen et al.
Source: check_circle
Crossref

Supplementary Table from Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study

2023-04-01 | Preprint
Contributors: Lili Mao; Meiyu Fang; Yu Chen; Xiaoting Wei; Jun Cao; Jing Lin; Peng Zhang; Ling Chen; Xiao Cao; Yujun Chen et al.
Source: check_circle
Crossref

Supplementary Table from Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study

2023-04-01 | Preprint
Contributors: Lili Mao; Meiyu Fang; Yu Chen; Xiaoting Wei; Jun Cao; Jing Lin; Peng Zhang; Ling Chen; Xiao Cao; Yujun Chen et al.
Source: check_circle
Crossref

Supplementary Table from Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study

2023-04-01 | Preprint
Contributors: Lili Mao; Meiyu Fang; Yu Chen; Xiaoting Wei; Jun Cao; Jing Lin; Peng Zhang; Ling Chen; Xiao Cao; Yujun Chen et al.
Source: check_circle
Crossref

Supplementary Table from Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study

2023-04-01 | Preprint
Contributors: Lili Mao; Meiyu Fang; Yu Chen; Xiaoting Wei; Jun Cao; Jing Lin; Peng Zhang; Ling Chen; Xiao Cao; Yujun Chen et al.
Source: check_circle
Crossref

Supplementary Table from Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study

2023-04-01 | Preprint
Contributors: Lili Mao; Meiyu Fang; Yu Chen; Xiaoting Wei; Jun Cao; Jing Lin; Peng Zhang; Ling Chen; Xiao Cao; Yujun Chen et al.
Source: check_circle
Crossref

Rs3746444 T>C locus in miR-499 increases the susceptibility to hepatocellular carcinoma: A meta-analysis 14812 subjects

World Journal of Gastrointestinal Oncology
2023-01-15 | Journal article
Part of ISSN: 1948-5204
Contributors: Jia-Kai Jiang; Han-Shen Chen; Wei-Feng Tang; Yu Chen; Jing Lin
Source: Self-asserted source
Jing Lin

Stereotactic body radiotherapy extends the clinical benefit of PD-1 inhibitors in refractory recurrent/metastatic nasopharyngeal carcinoma

Radiation Oncology
2022-12 | Journal article
Part of ISSN: 1748-717X
Contributors: Jing Lin; Qiaojuan Guo; Zengqing Guo; Tianzhu Lu; Gang Chen; Shaojun Lin; Mei Chen; Chuanben Chen; Jianping Lu; Jingfeng Zong et al.
Source: Self-asserted source
Jing Lin

An EGFR L858R mutation identified in 1862 Chinese NSCLC patients can be a promising neoantigen vaccine therapeutic strategy

Frontiers in Immunology
2022-11-23 | Journal article
Part of ISSN: 1664-3224
Contributors: Jing Lin; Jun Liu; Shi-guang Hao; Bin Lan; Xiao-bin Zheng; Jia-ni Xiong; Ying-qian Zhang; Xuan Gao; Chuan-ben Chen; Ling Chen et al.
Source: Self-asserted source
Jing Lin

Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study

Clinical Cancer Research
2022-11-01 | Journal article | Author
Part of ISSN: 1078-0432
Part of ISSN: 1557-3265
Contributors: Lili Mao; meiyu fang; Yu Chen; Xiaoting Wei; JUN CAO; Jing Lin; Peng Zhang; Ling Chen; XIAO CAO; Yujun Chen et al.
Source: Self-asserted source
Jing Lin
grade
Preferred source (of 2)‎

Lack of Association Between <i>PDCD-1</i> Polymorphisms and Colorectal Cancer Risk: A Case-Control Study

Immunological Investigations
2022-08-18 | Journal article
Part of ISSN: 0882-0139
Part of ISSN: 1532-4311
Contributors: Jing Lin; Hanshen Chen; Yufang Huang; Weifeng Tang; Sheng Zhang; Yu Chen
Source: Self-asserted source
Jing Lin

CCND1 Amplification Profiling Identifies a Subtype of Melanoma Associated With Poor Survival and an Immunosuppressive Tumor Microenvironment

Frontiers in Immunology
2022-07-01 | Journal article
Part of ISSN: 1664-3224
Contributors: Jun Liu; Jing Lin; Xuefeng Wang; Xiaobin Zheng; Xuan Gao; Yingying Huang; Gang Chen; Jiani Xiong; Bin Lan; Chuanben Chen et al.
Source: Self-asserted source
Jing Lin

Durable complete response to neoantigen-loaded dendritic-cell vaccine following anti-PD-1 therapy in metastatic gastric cancer

npj Precision Oncology
2022-06-03 | Journal article
Part of ISSN: 2397-768X
Contributors: Zengqing Guo; Yuan Yuan; Chao Chen; Jing Lin; Qiwang Ma; Geng Liu; Yan Gao; Ying Huang; Ling Chen; Li-Zhu Chen et al.
Source: Self-asserted source
Jing Lin

A high homologous recombination deficiency score is associated with poor survival and a non-inflamed tumor microenvironment in head and neck squamous cell carcinoma patients

Oral Oncology
2022-05 | Journal article
Part of ISSN: 1368-8375
Contributors: Yu Chen; Xiaobin Zheng; Jing Lin; Xuan Gao; Jiani Xiong; Jun Liu; Zhaodong Fei; Chuanben Chen
Source: Self-asserted source
Jing Lin

Prevalence of<i>PRKDC</i>mutations and association with response to immune checkpoint inhibitors in solid tumors

Molecular Oncology
2020-09 | Journal article
Part of ISSN: 1574-7891
Part of ISSN: 1878-0261
Contributors: Yu Chen; Yi Li; Yanfang Guan; Yingying Huang; Jing Lin; Lizhu Chen; Jin Li; Gang Chen; Leong Kin Pan; Xuefeng Xia et al.
Source: Self-asserted source
Jing Lin

Investigation of <i>Leptin</i> and its receptor (<i>LEPR</i>) for single nucleotide polymorphisms in colorectal cancer: a case-control study involving 2,306 subjects.

American journal of translational research
2020-07-15 | Journal article
Source: Self-asserted source
Jing Lin

PPARG rs3856806 C>T Polymorphism Increased the Risk of Colorectal Cancer: A Case-Control Study in Eastern Chinese Han Population.

Frontiers in oncology
2019-02-19 | Journal article
Source: Self-asserted source
Jing Lin

Expression and prognostic roles of magnesium-dependent phosphatase-1 in gastric cancer.

European review for medical and pharmacological sciences
2017-06-01 | Journal article
Source: Self-asserted source
Jing Lin

Polymorphisms in the xenobiotic transporter Multidrug Resistance 1 (MDR1) and interaction with meat intake in relation to risk of colorectal cancer in a Danish prospective case-cohort study.

BMC cancer
2009-11-21 | Journal article
Source: Self-asserted source
Jing Lin

Insulin receptor substrate-2 (IRS-2) rs1805097 G>A polymorphism is associated with colorectal cancer susceptibility: a meta-analysis involving 11,234 subjects

Journal article
Source: Self-asserted source
Jing Lin

Lack of association between MicroRNA-146a rs2910164 C > G polymorphism and risk of gastric carcinoma: a case-control study and a meta-analysis

Int J Clin Exp Med
Journal article
Source: Self-asserted source
Jing Lin